Dr. Lal Pathlabs Limited · NSE:LALPATHLAB
Dr. Lal Pathlabs — H1 FY23 Earnings Presentation
30 slides from Dr. Lal Pathlabs's earnings presentation, Nov 8, 2022
Slide 1: Exchange filing cover letter
November 08, 2022 National Stock Exchange of India Limited BSE Limited Exchange Plaza, Corporate Relationship Department Plot No. C/1, G Block, Phiroze Jeejeebhoy Towers Bandra Kurla Complex, Bandra (E) Dalal Street Mumbai – 400 051 Mumbai – 400 001 Subject: Investors Presentation on Un-audited Fina
Slide 2: Q2 & H1 FY23 Results Presentation
Dr. Lal PathLabs Limited (DLPL) Q2 & H1 FY23 Results Presentation November 8, 2022
Slide 3: Disclaimer
Disclaimer By attending the meeting / telephonic call where this presentation is made, or by reading the presentation materials, you agree to be bound by the following limitations: The information in this presentation has been prepared by Dr. Lal PathLabs Limited (the “Company”) for use in presentat
Slide 4: Table of Contents
Table of Contents Dr. Lal PathLabs – At a Glance 4 Overview of Dr. Lal PathLabs 5 Key Performance Highlights 7 Financials 9 Financial Highlights 10 Operating Highlights 11 Management Commentary 12 Corporate Overview 13 Shareholding 28 Contact Us 29 DISCLAIMER: This presentation may contain ‘forward-
Slide 5: Dr. Lal PathLabs – At a Glance
Dr. Lal PathLabs – At a Glance India’s Leading & Trusted 20% 20% 120% Diagnostics Company Largest* 3 Year Revenue 3-Year PAT Equity Dividend CAGR CAGR for FY 21-22 diagnostics 70+ years of experience chain in the in the field of diagnostics country with ~44% Rs. 419 crore (Net) PAN India ROCE Cash &
Slide 6: Overview of Dr. Lal PathLabs
Overview of Dr. Lal PathLabs Pan-India Unique and Established integrated successful brand coverage Varied Offerings operating model 277 clinical labs Well-positioned (including National Reference Lab at Catalogue of 491 test Scalable model in one of the Established consumer Delhi and Regional panels
Slide 7: Q2 FY23 Snapshot
Q2 FY23 Snapshot INR 534 Cr +7% INR 514 Cr +15% INR 20 Cr -61% Total Revenue Non Covid Revenue Covid Revenue 7 MN +9% 19 MN +12% Non-Covid Patients Non-Covid Samples INR 150 Cr 28% INR 86 Cr 16% Normalised EBITDA* Margin Normalised PAT** Margin * Normalised EBITDA excl. RSU, CSR **Normalised PAT exc
Slide 8: Key Performance Highlights
Key Performance Highlights In Q2 FY23: • Non-Covid Revenues grew by 15% Y-o-Y to Rs. 514 crore, Total Revenues higher by 7% Y-o-Y to Rs. 534 crore • Normalised EBITDA* came in at Rs. 150 crore, a margin of 28% • Normalised Profit After Tax** at Rs. 86 crore, a margin of 16% A healthy balance sheet w
Slide 9: Non-COVID, COVID & Allied Revenue
Non-COVID, COVID & Allied Revenue Rs. Cr. Total 498 497 486 503 534 482 514 448 438 420 37 49 49 4 10 2 8 7 10 12 1 8 10 2 8 Q2 FY22 Q3 FY22 Q4 FY22 Q1 FY23 Q2 FY23 Non COVID COVID* COVID Allied 1** COVID Allied 2*** *COVID includes RTPCR and Antibody tests; **COVID Allied 1 includes IL-6 & D-Dimer;
Slide 10: Financials
Financials Particulars (Rs. Cr.) Q2 FY23 Q2 FY22 Gr % FH'23 FH'22 Gr % Revenue 533.8 498.4 7.1% 1,036.5 1,105.0 -6.2% Expenditure 390.0 357.0 775.2 774.6 EBITDA 143.8 141.5 261.3 330.4 Stock based comp., CSR cost 6.3 10.7 14.3 20.8 Normalised EBITDA 150.1 152.2 -1.4% 275.6 351.2 -21.5% Normalised Ma
Slide 11: Financial Highlights
Financial Highlights All figures in Rs. Crore Revenue Normalised EBITDA* Normalised PBT** Normalised PAT** Non Covid Covid 498 534 -61% 20 50 152 150 131 117 96 86 +15% 514 448 Margin Margin Margin Margin Margin Margin 31% 28% 26% 22% 19% 16% Q2 FY22 Q2 FY23 Q2 FY22 Q2 FY23 Q2 FY22 Q2 FY23 Q2 FY22 Q
Slide 12: Operating Highlights
Operating Highlights No. of Clinical Laboratories No. of PSCs No. of PUPs +77 +2,162 +4,173 277 4,731 9,247 10,599 200 216 231 3,705 6,426 6,995 2,569 3,095 FY19 FY20 FY21 FY22 FY19 FY20 FY21 FY22 FY19 FY20 FY21 FY22 No. of Patients (Mn) No. of Samples (Mn) +55% +58% 27.3 66.0 17.6 19.4 20.3 47.7 49
Slide 13: Management Commentary
Management Commentary Commenting on the results announcement, (Hony) Commenting on the results announcement, Dr. Om Commenting on the results announcement, Mr. Brig. Dr. Arvind Lal, Executive Chairman said: Manchanda, Managing Director said: Bharath Uppiliappan, Chief Executive Officer said: “Dr Lal
Slide 14: Corporate Overview
Corporate Overview
Slide 15: Vision, Mission & Values
Vision, Mission & Values Be the most trusted Customer First healthcare partner, enabling healthier VISION lives Ethics & Integrity To be an undisputed market Quality leader by providing accessible, VALUES affordable, timely and quality healthcare, diagnostics, applying MISSION Accountability insight
Slide 16: Vibrant Outlook
Vibrant Outlook Target to grow ahead of the Evaluate best fit inorganic opportunities in South, and industry leverage expertise of recently acquired Suburban brand in West Higher contribution from bundling of tests – ‘Swasthfit’ Strongly develop Rest of India geographies, through Deeper Penetration
Slide 17: DLPL Strategy for future growth
DLPL Strategy for future growth 01 Strengthen Expansion in Offering Existing Operations 04 02 Expand management Geographic of hospital based and expansion 03 clinical laboratories Classification: Restricted 16
Slide 18: DLPL Strategy for future growth
DLPL Strategy for future growth • Boosting quality & reliability standards • Improving turnaround times for testing • Grow basic radiology practice Strengthen Existing • Online initiatives and data analytics Operations • Investment in branding • Improve breadth of diagnostic testing • Cutting edge t
Slide 19: Leveraging digital infrastructure to make life easier for patient
Leveraging digital infrastructure to make life easier for patient Digital Lab Logistics Automation • Self Registration Kiosk for patients • Field Executive Mobile App for Route • Integrated payment gateway for online payment Traceability & Field Executive Tracking • Self Report printing Kiosks for 2
Slide 20: Consistent investments in R&D
Consistent investments in R&D DSIR recognized In House R&D unit with Sanger an experienced team Sequencing, Single Variant of research scientists and doctors Sickle Cell Trio Leigh Syndrome Prenatal Mitochondrial Mutation Mutation Detection Successful Detection commercialization of tests Jawaharlal
Slide 21: Genevolve: The Genomics initiative
Genevolve: The Genomics initiative GENEVOLVE brings the dawn of a new era of Genomic testing! Genevolve: Genomics division focuses on Genetic testing Offers wide range of key tests related to Oncogenomics, Neurogenomics, Rare disease & Pre- natal/ Post-natal Tests are carried out using cutting edge
Slide 22: In-house adoption of Digital Histopathology
In-house adoption of Digital Histopathology Opportunities created by Digital Reporting of Digital Histopathology Breast cancer Panels using AI based • Enhanced access to second algorithms opinion, synchronous review of slides • Enhanced quality of reporting • Potential for insourcing services • Leve
Slide 23: Highest Quality Standards in the Industry
Highest Quality Standards in the Industry Best in the Industry CAP Proficiency Testing Score at 97.9% for National Reference Lab Consistently high EQAS Performance Testing Score at 98.6% for Satellite Labs NABL Accreditation granted to 18 Labs for processing Covid-19 samples 100+ Quality Digitally e
Slide 24: Realtime Quality Control via automated review and analysis
Realtime Quality Control (QC) via automated review and analysis Manual fetching, Benefits to DLPL consolidation and analysis of the QC data sharing with Quality Control data respective labs for is tedious and RCA & CAPA done on Provides visibility of the QC analytics lengthy near real time basis on
Slide 25: Best in class Logistics and Supply Chain management
Best in class Logistics and Supply Chain management Real time Automated Productivity Real time Real time Field Cash collection and route service sample Executive process with planning monitoring tracking tracking clients visibility Control tower Classification: Restricted 25
Slide 26: Enhanced Customer Experience in Home Collection
Enhanced Customer Experience in Home Collection Auto Routing engine to dynamically allocate Real time phlebo the booking to nearest visibility to the patient available phlebotomist Variable model Real time slot which grows confirmation with business to patient volume ECG at home Automated service an
Slide 27: Experienced Management team
Experienced Management team (Hony.) Brig. Dr. Arvind Lal Dr. Om Manchanda Dr. Vandana Lal Bharath Uppiliappan Ved Prakash Goel Executive Chairman Managing Director Whole-time Director Chief Executive Officer Group Chief Financial Officer Shankha Banerjee Munender Soperna Rajat Kalra Manoj Garg Compa
Slide 28: Key Awards & Recognition
Key Awards & Recognition ICICI Lombard & Dr. Om Manchanda Business Standard Star GAPIO Excellence in Financial Express CFO CFO100 Roll of CSR Award 2022 honoured and Best Brands CNBC TV18 India SME of the year 2022 Diagnostics Award of the year 2022 Honour 2022 awarded as Healthcare 2022 Risk Manage
Slide 29: Shareholding as of 30th September, 2022
Shareholding as of 30th September, 2022 26.8% FIIs, FPIS, Foreign Company & NRIs 55.1% Promoter and Promoter 14.2% Group Others 3.9% Mutual Funds* *Mutual Funds includes Alternate Investment Funds as well 28
Slide 30: Contact Us
Contact Us About Dr. Lal PathLabs Limited (DLPL) Dr. Lal PathLabs Limited is one of India’s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests